Switch theme
Sign up to access all valuation multiples
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company developing novel treatments for medical conditions with unmet needs. The company has a pipeline based on the receptors involved in the regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy in phase I/II development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation. Traumakine, the company's investigational intravenous interferon beta-1a is an anti-viral and anti-inflammatory agent, being tested for the prevention of complications that arise from cytokine release syndrome, or hyperinflammatory conditions.
2006
25
LTM Revenue $3.8M
LTM EBITDA -$15.0M
$370M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Faron Pharmaceuticals has a last 12-month revenue (LTM) of $3.8M and a last 12-month EBITDA of -$15.0M.
In the most recent fiscal year, Faron Pharmaceuticals achieved revenue of n/a and an EBITDA of -$29.1M.
Faron Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Faron Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.2M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 5% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$15.0M | XXX | -$29.1M | XXX | XXX | XXX |
| EBITDA Margin | -390% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$16.2M | XXX | -$25.1M | XXX | XXX | XXX |
| EBIT Margin | -421% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$19.8M | XXX | -$34.8M | XXX | XXX | XXX |
| Net Margin | -515% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Faron Pharmaceuticals's stock price is GBP 2 (or $3).
Faron Pharmaceuticals has current market cap of GBP 273M (or $367M), and EV of GBP 276M (or $370M).
See Faron Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $370M | $367M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Faron Pharmaceuticals has market cap of $367M and EV of $370M.
Faron Pharmaceuticals's trades at n/a EV/Revenue multiple, and -12.7x EV/EBITDA.
Equity research analysts estimate Faron Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Faron Pharmaceuticals has a P/E ratio of -15.5x.
See valuation multiples for Faron Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $367M | XXX | $367M | XXX | XXX | XXX |
| EV (current) | $370M | XXX | $370M | XXX | XXX | XXX |
| EV/Revenue | 80.5x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -20.7x | XXX | -12.7x | XXX | XXX | XXX |
| EV/EBIT | -19.1x | XXX | -14.8x | XXX | XXX | XXX |
| EV/Gross Profit | 1577.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -15.5x | XXX | -10.5x | XXX | XXX | XXX |
| EV/FCF | -25.6x | XXX | -11.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFaron Pharmaceuticals's last 12 month revenue growth is 42%
Faron Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Faron Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Faron Pharmaceuticals's rule of X is -285% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Faron Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -390% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 29% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -285% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Faron Pharmaceuticals acquired XXX companies to date.
Last acquisition by Faron Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Faron Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Faron Pharmaceuticals founded? | Faron Pharmaceuticals was founded in 2006. |
| Where is Faron Pharmaceuticals headquartered? | Faron Pharmaceuticals is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| How many employees does Faron Pharmaceuticals have? | As of today, Faron Pharmaceuticals has 25 employees. |
| Is Faron Pharmaceuticals publicy listed? | Yes, Faron Pharmaceuticals is a public company listed on LON. |
| What is the stock symbol of Faron Pharmaceuticals? | Faron Pharmaceuticals trades under FARN ticker. |
| When did Faron Pharmaceuticals go public? | Faron Pharmaceuticals went public in 2015. |
| Who are competitors of Faron Pharmaceuticals? | Similar companies to Faron Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Faron Pharmaceuticals? | Faron Pharmaceuticals's current market cap is $367M |
| What is the current revenue of Faron Pharmaceuticals? | Faron Pharmaceuticals's last 12 months revenue is $3.8M. |
| What is the current revenue growth of Faron Pharmaceuticals? | Faron Pharmaceuticals revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Faron Pharmaceuticals? | Current revenue multiple of Faron Pharmaceuticals is 80.5x. |
| Is Faron Pharmaceuticals profitable? | Yes, Faron Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Faron Pharmaceuticals? | Faron Pharmaceuticals's last 12 months EBITDA is -$15.0M. |
| What is Faron Pharmaceuticals's EBITDA margin? | Faron Pharmaceuticals's last 12 months EBITDA margin is -390%. |
| What is the current EV/EBITDA multiple of Faron Pharmaceuticals? | Current EBITDA multiple of Faron Pharmaceuticals is -20.7x. |
| What is the current FCF of Faron Pharmaceuticals? | Faron Pharmaceuticals's last 12 months FCF is -$12.1M. |
| What is Faron Pharmaceuticals's FCF margin? | Faron Pharmaceuticals's last 12 months FCF margin is -314%. |
| What is the current EV/FCF multiple of Faron Pharmaceuticals? | Current FCF multiple of Faron Pharmaceuticals is -25.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
